Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

globenewswire

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD) – NEWSnet – News… as it used to be

More Press Releases

May 1, 2026

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Esperion Therapeutics, Inc. (NASDAQ: ESPR)

May 1, 2026

Free AI Crypto Trading App by AriseAlpha: Smart Automated Trading in 2026

May 1, 2026

Transaction in Own Shares

May 1, 2026

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Esperion Therapeutics, Inc. (NASDAQ: ESPR)

Free AI Crypto Trading App by AriseAlpha: Smart Automated Trading in 2026

Transaction in Own Shares

Building Better Bones Together: Osteoporosis Awareness and Prevention Month 2026